IL271813A - Recombinant uricase enzyme - Google Patents

Recombinant uricase enzyme

Info

Publication number
IL271813A
IL271813A IL271813A IL27181320A IL271813A IL 271813 A IL271813 A IL 271813A IL 271813 A IL271813 A IL 271813A IL 27181320 A IL27181320 A IL 27181320A IL 271813 A IL271813 A IL 271813A
Authority
IL
Israel
Prior art keywords
recombinant uricase
uricase enzyme
enzyme
recombinant
uricase
Prior art date
Application number
IL271813A
Other languages
English (en)
Hebrew (he)
Inventor
Aditi R Deshpande
Danica Grujic
Sridhar Govindarajan
Mark Welch
Original Assignee
Allena Pharmaceuticals Inc
Aditi R Deshpande
Danica Grujic
Sridhar Govindarajan
Mark Welch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allena Pharmaceuticals Inc, Aditi R Deshpande, Danica Grujic, Sridhar Govindarajan, Mark Welch filed Critical Allena Pharmaceuticals Inc
Publication of IL271813A publication Critical patent/IL271813A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048Uricase (1.7.3.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y107/00Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL271813A 2017-07-07 2020-01-02 Recombinant uricase enzyme IL271813A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529726P 2017-07-07 2017-07-07
US201862678511P 2018-05-31 2018-05-31
PCT/US2018/041015 WO2019010369A1 (en) 2017-07-07 2018-07-06 RECOMBINANT ENZYME URICASE

Publications (1)

Publication Number Publication Date
IL271813A true IL271813A (en) 2020-02-27

Family

ID=64951239

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271813A IL271813A (en) 2017-07-07 2020-01-02 Recombinant uricase enzyme

Country Status (8)

Country Link
US (2) US20200308534A1 (https=)
EP (1) EP3655527A4 (https=)
JP (2) JP2020530282A (https=)
CN (1) CN111373034A (https=)
AU (1) AU2018297309A1 (https=)
CA (1) CA3069197A1 (https=)
IL (1) IL271813A (https=)
WO (1) WO2019010369A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN114480320B (zh) * 2022-02-28 2024-01-16 复旦大学 重组夜猴尿酸酶及其应用
CN118497162B (zh) * 2024-05-24 2025-05-16 广东少和生物科技有限公司 黑酵母菌尿酸氧化酶及其突变体和应用
CN119876071B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 低免疫原性的高活性人源尿酸氧化酶突变体
CN119876069B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20050049166A1 (en) * 2003-08-29 2005-03-03 Huang Tsao-Chin Clare Enzyme-based cleaning composition and method of use
GB0326676D0 (en) * 2003-11-15 2003-12-17 Astrazeneca Ab Protein
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
WO2006012438A2 (en) 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク. 陽イオン界面活性剤によるタンパク質の精製
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
CN101390969A (zh) * 2008-11-03 2009-03-25 中国人民解放军军事医学科学院生物工程研究所 降低血液中尿酸浓度的药物
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
DE112011100467B4 (de) * 2010-02-05 2018-07-12 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Genauigkeit
CN102586315A (zh) * 2012-02-21 2012-07-18 章泽人 一种低尿酸分泌量益生菌及其制备方法
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN104342415A (zh) * 2014-07-08 2015-02-11 吉林省金梓源生物科技有限公司 一种重组尿酸酶的制备方法
AR101504A1 (es) * 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
CN106554948B (zh) 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
KR20180120753A (ko) 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN107308452A (zh) * 2017-05-29 2017-11-03 钟术光 一种稳定生物活性材料的组合物的制备方法
GB201713732D0 (en) * 2017-08-25 2017-10-11 Alta Innovations Ltd Tat expression system
CN109223707B (zh) 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
CN109846909B (zh) * 2019-01-31 2022-03-22 武汉康复得生物科技股份有限公司 可在肠道中催化尿酸降解的组合物及其制备方法和应用
KR20250041198A (ko) * 2019-05-10 2025-03-25 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소

Also Published As

Publication number Publication date
EP3655527A1 (en) 2020-05-27
EP3655527A4 (en) 2021-06-16
US20200071681A1 (en) 2020-03-05
JP2023126877A (ja) 2023-09-12
CA3069197A1 (en) 2019-01-10
CN111373034A (zh) 2020-07-03
WO2019010369A1 (en) 2019-01-10
US20200308534A1 (en) 2020-10-01
JP2020530282A (ja) 2020-10-22
AU2018297309A1 (en) 2020-01-30
US10815461B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
IL282092B (en) Engineered enzymes
SG11202105121WA (en) Crispr-cas12j enzyme and system
IL271504A (en) Modified L-asparaginase
IL281171A (en) Cellulose-synthase-like enzymes and their uses
IL271813A (en) Recombinant uricase enzyme
SG11201800394WA (en) Novel endos mutant enzyme
EP3250692A4 (en) Novel promoter and uses thereof
IL274284A (en) Transglutaminase variants
PT3609908T (pt) Enzimas lactase com propriedades melhoradas
GB201712597D0 (en) Improved bioreactors
SG11202012109UA (en) Engineered phosphopentomutase variant enzymes
DK3642343T3 (en) Improved protein expression strains
EP3279323A4 (en) Amadoriase having improved specific activity
EP3160949A4 (en) Enzyme interacting agents
EP3641740A4 (en) TARGETED THERAPEUTICS
ZA202007357B (en) Lipolytic enzyme variants
IL250272A0 (en) Enzyme without sugar residue and its uses
GB201803491D0 (en) Novel enzymes
EP3641647A4 (en) TARGETED THERAPEUTICS
GB201605354D0 (en) Modified enzyme
GB201604750D0 (en) Enzyme comositions
HK40031083A (en) Recombinant uricase enzyme
GB201409709D0 (en) Improved deoxyribonuclease enzymes
AU2017903865A0 (en) Recombinant Microorganisms
HK40026010A (en) Modified car-t